We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Read MoreHide Full Article
Key Takeaways
MRK's I-DXd earned the FDA's Breakthrough Therapy tag for extensive-stage small cell lung cancer.
The FDA's decision was based on data from the phase II IDeate-Lung01 study of I-DXd.
Merck co-develops I-DXd with Daiichi, expanding an ADC-focused cancer drug collaboration.
Merck (MRK - Free Report) announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult patients with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy.
The FDA’s Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests that a drug may significantly improve over existing treatments on one or more important clinical measures.
The FDA’s latest decision was based on data from the phase II IDeate-Lung01 study with support from the phase I/II IDeate-PanTumor01 study. The IDeate-Lung01 study evaluated the safety and efficacy of I-DXdin in the given patient population.
MRK Stock Performance
Year to date, shares of Merck have plunged 15.3% compared with the industry’s decline of 2.8%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for I-DXd & Other ADC Candidates
Besides extensive-stage small cell lung cancer, I-DXd is being evaluated in separate phase III studies for treating esophageal cancer and prostate cancer. Developed by Daiichi Sankyo, this ADC drug candidate already enjoys an orphan drug designation for treating small-cell lung cancer in the United States, Europe and some other countries.
Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Patritumab deruxtecan is being developed in late-stage studies for breast cancer, while raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications.
Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
In January 2025, the FDA approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy. The FDA approved Datroway for its second indication, non-small-cell lung cancer, in June.
Pfizer (PFE - Free Report) also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023.
Following this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2024 and in the first half of 2025.
Image: Shutterstock
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
Key Takeaways
Merck (MRK - Free Report) announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult patients with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy.
The FDA’s Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests that a drug may significantly improve over existing treatments on one or more important clinical measures.
The FDA’s latest decision was based on data from the phase II IDeate-Lung01 study with support from the phase I/II IDeate-PanTumor01 study. The IDeate-Lung01 study evaluated the safety and efficacy of I-DXdin in the given patient population.
MRK Stock Performance
Year to date, shares of Merck have plunged 15.3% compared with the industry’s decline of 2.8%.
Image Source: Zacks Investment Research
MRK & Daiichi's Deal for I-DXd & Other ADC Candidates
Besides extensive-stage small cell lung cancer, I-DXd is being evaluated in separate phase III studies for treating esophageal cancer and prostate cancer. Developed by Daiichi Sankyo, this ADC drug candidate already enjoys an orphan drug designation for treating small-cell lung cancer in the United States, Europe and some other countries.
Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan.
In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics.
Patritumab deruxtecan is being developed in late-stage studies for breast cancer, while raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications.
Competition in the ADC Space
ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors.
Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca (AZN - Free Report) , which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers.
In January 2025, the FDA approved AZN and Daiichi’s second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy. The FDA approved Datroway for its second indication, non-small-cell lung cancer, in June.
Pfizer (PFE - Free Report) also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023.
Following this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer’s revenues in 2024 and in the first half of 2025.
MRK's Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.